Clinical Focus ›› 2025, Vol. 40 ›› Issue (11): 1043-1046.doi: 10.3969/j.issn.1004-583X.2025.11.013
Previous Articles Next Articles
-
Received:2025-07-30Online:2025-11-20Published:2025-12-02
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.11.013
| [1] | Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 2200879. doi: 10.1183/13993003.00879-2022. |
| [2] | Hu P, Xu Y, Jiang Y, et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11[J]. Eur J Pharmacol, 2022, 928:175093. doi: 10.1016/j.ejphar.2022.175093. |
| [3] |
Fang W, Xie S, Deng W. Ferroptosis mechanisms and regulations in cardiovascular diseases in the past, present, and future[J]. Cell Biol Toxicol, 2024, 40(1): 17. doi: 10.1007/s10565-024-09853-w.
pmid: 38509409 |
| [4] |
Li X, Tan J, Wan J, et al. Cell death in pulmonary arterial hypertension[J]. Int J Med Sci, 2024, 21(10): 1840-1851. doi: 10.7150/ijms.93902.
pmid: 39113898 |
| [5] | Chen Y, Li X, Wang S, et al. Targeting iron metabolism and ferroptosis as novel therapeutic approaches in cardiovascular diseases[J]. Nutrients, 2023, 15(3): doi: 10.3390/nu15030591. |
| [6] | 吴楠, 杨涛, 胡玉原, 等. 铁稳态、铁死亡与心血管疾病[J]. 临床与病理杂志, 2024, 44(2):295-306. doi: 10.11817/j.issn.2095-6959.2024.240119. |
| [7] |
Li J, Cao F, Yin HL, et al. Ferroptosis: Past, present and future[J]. Cell Death Dis, 2020, 11(2): 88. doi: 10.1038/s41419-020-2298-2.
pmid: 32015325 |
| [8] | Protchenko O, Baratz E, Jadhav S, et al. Iron Chaperone poly rc binding protein 1 protects mouse liver from lipid peroxidation and steatosis[J]. Hepatology, 2021, 73(3): 1176-1193. doi: 10.1002/hep.31328. |
| [9] | Qin Y, Qiao Y, Wang D, et al. Ferritinophagy and ferroptosis in cardiovascular disease: Mechanisms and potential applications[J]. Biomed Pharmacother, 2021, 141(111872). doi: 10.1016/j.biopha.2021.111872. |
| [10] | Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease[J]. Biomed Pharmacother, 2022, 145:112423. doi: 10.1016/j.biopha.2021.112423. |
| [11] | Su LJ, Zhang JH, Gomez H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis[J]. Oxid Med Cell Longev, 2019, 2019:5080843. doi: 10.1155/2019/5080843. |
| [12] | Xie LH, Fefelova N, Pamarthi SH, et al. Molecular mechanisms of ferroptosis and relevance to cardiovascular disease[J]. Cells, 2022, 11(17): doi: 10.3390/cells11172726. |
| [13] |
Zhang F, Liu H. Identification of ferroptosis-associated genes exhibiting altered expression in pulmonary arterial hypertension[J]. Math Biosci Eng, 2021, 18(6): 7619-7630. doi: 10.3934/mbe.2021377.
pmid: 34814266 |
| [14] | Kazmirczak F, Vogel NT, Prisco SZ, et al. Ferroptosis integrates mitochondrial derangements and pathological inflammation to promote pulmonary hypertension[J]. 2024, 23:2023.01.19.524721.doi: 10.1101/2023.01.19.524721. |
| [15] |
Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation[J]. Cell Death Dis, 2019, 10(11): 822. doi: 10.1038/s41419-019-2064-5.
pmid: 31659150 |
| [16] | Xie SS, Deng Y, Guo SL, et al. Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation[J]. Sci Rep, 2022, 12(1): 3056. doi: 10.1038/s41598-022-06848-7. |
| [17] | Liao J, Xie SS, Deng Y, et al. PRDX6-mediated pulmonary artery endothelial cell ferroptosis contributes to monocrotaline-induced pulmonary hypertension[J]. Microvasc Res, 2023, 146:104471. doi: 10.1016/j.mvr.2022.104471. |
| [18] | Ahola S, Langer T. Ferroptosis in mitochondrial cardiomyopathy[J]. Trends Cell Biol, 2024, 34(2): 150-160. doi: 10.1016/j.tcb.2023.06.002. |
| [19] |
Kazmirczak F, Vogel NT, Prisco SZ, et al. Ferroptosis mediated inflammation promotes pulmonary hypertension[J]. Circ Res, 2024, 135(11):1067-1083. doi: 10.1161/circresaha.123.324138.
pmid: 39421926 |
| [20] | Song J, Chen Y, Chen Y, et al. Ferrostatin-1 blunts right ventricular hypertrophy and dysfunction in pulmonary arterial hypertension by suppressing the HMOX1/GSH signaling[J]. J Cardiovasc Transl Res, 2024, 17(1): 183-196. doi: 10.1007/s12265-023-10423-4. |
| [21] | Chen T, Ding L, Zhao M, et al. Recent advances in the potential effects of natural products from traditional Chinese medicine against respiratory diseases targeting ferroptosis[J]. Chin Med, 2024, 19(1): 49. doi: 10.1186/s13020-024-00918-w. |
| [22] | Lv J, Shi S, Fu Z, et al. Exploring the inflammation-related mechanisms of Lingguizhugan decoction on right ventricular remodeling secondary to pulmonary arterial hypertension based on integrated strategy using UPLC-HRMS, systems biology approach, and experimental validation[J]. Phytomedicine, 2024, 132:155879. doi: 10.1016/j.phymed.2024.155879. |
| [23] |
Che H, Yi J, Zhao X, et al. Characterization of PKCα-rutin interactions and their application as a treatment strategy for pulmonary arterial hypertension by inhibiting ferroptosis[J]. Food Funct, 2024, 15(2): 779-793. doi: 10.1039/d3fo01306e.
pmid: 38126185 |
| [24] | Chen F, Wang H, Yan J, et al. Grape seed proanthocyanidin reverses pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension by down-regulating HSP70[J]. Biomed Pharmacother, 2018, 101(123-128). doi: 10.1016/j.biopha.2018.02.037. |
| [25] | Wang L, Liu C, Wang L, et al. Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis[J]. Eur J Pharmacol, 2023, 944:175516. doi: 10.1016/j.ejphar.2023.175516. |
| [1] | . [J]. Clinical Focus, 2025, 40(3): 275-280. |
| [2] | . [J]. Clinical Focus, 2024, 39(2): 188-192. |
| [3] | . [J]. Clinical Focus, 2023, 38(9): 838-844. |
| [4] | Wei Qingyuan, Yin Xufang, Li Jiaojiao. Application of BNP, Hcy, AVP, CPT in disease development and efficacy evaluation of patients with chronic pulmonary heart disease [J]. Clinical Focus, 2021, 36(7): 600-603. |
| [5] | . [J]. CLINICAL FOCUS, 2013, 28(10): 1164-1166. |
| [6] | . [J]. Clinical Focus, 2012, 27(18): 1624-1626. |
| [7] | . [J]. CLINICAL FOCUS, 2011, 26(19): 1730-1732. |
| [8] | . [J]. CLINICAL FOCUS, 2010, 25(1): 68-69. |
| [9] | ZHANG Yu-qing;ZHANG Xiu-wei;ZHU Ying;YANG Jian. Effect of atorvastatin on right ventricular function in chronic obstructive pulmonary disease patients with chronic cor pulmonale [J]. CLINICAL FOCUS, 2009, 24(22): 1933-1936. |
| [10] | ZHU Yan-hui;SONG Qiao-feng;WANG Xi-zhu;JIA Hong-juan;LIU Chun-rong;YAO Yan-min;DONG Yan. Different doses of atorvastatin on serum lipids, big-endothelines,brain natriuretic peptide and pulmonary artery pressure in hyperlipidemic patients with chronic cor pulmonale [J]. CLINICAL FOCUS, 2009, 24(7): 567-570. |
| [11] | . [J]. CLINICAL FOCUS, 2009, 24(3): 248-249. |
| [12] | . [J]. CLINICAL FOCUS, 2008, 23(7): 490-491. |
| [13] | . [J]. CLINICAL FOCUS, 2008, 23(3): 184-185. |
| [14] | . [J]. CLINICAL FOCUS, 2007, 22(23): 1697-1697. |
| [15] | . [J]. CLINICAL FOCUS, 2007, 22(18): 1367-1368. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||